Related Experiment Videos
A solid phase enzyme immunoassay for serum amyloid A (SAA) protein. Clinical evaluation
1Department of Chemical Pathology, Leeds University, U.K.
Journal of Immunological Methods
|January 24, 1991
Summary
A new enzyme-linked immunosorbent assay can rapidly and accurately measure serum amyloid A protein. This protein is a sensitive marker for the body's acute-phase response to inflammation or infection.
Area of Science:
- Biochemistry
- Immunology
- Clinical Chemistry
Background:
- The acute-phase response is a critical indicator of inflammation and infection.
- Serum amyloid A (SAA) protein is a key biomarker during the acute-phase response.
- Accurate and efficient measurement of SAA is essential for clinical diagnostics.
Purpose of the Study:
- To develop a novel enzyme-linked immunosorbent assay (ELISA) for quantifying serum amyloid A protein.
- To validate the use of commercially available antisera for SAA detection.
- To establish SAA measurement as a reliable marker for the acute-phase response.
Main Methods:
- Development of an ELISA using Immulon II microtitre plates.
- Coating plates with undenatured sera via overnight incubation at 4°C.
- Utilizing commercially available antisera for antibody detection.
Main Results:
- The developed ELISA is simple, rapid, precise, sensitive, and safe.
- The assay effectively measures serum amyloid A protein levels.
- Demonstrated suitability for high-throughput sample processing.
Conclusions:
- The novel ELISA provides a robust method for SAA quantification.
- SAA protein is confirmed as a sensitive marker for the acute-phase response.
- This assay facilitates efficient monitoring of inflammatory and infectious conditions.